REYKJAVIK, ICELAND and LONDON, UK (November 06, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and…
In-Vitro Data Confirms Strong Protection Against H1N1 Influenza via Physical Barrier Mechanism Ra’anana, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) --…
- Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron® Phase 2b trial, prespecified…
Kennewick, WA, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) – The Company continues to prioritize securing FDA…
PolyPid's Lead Candidate Recognized for Addressing Critical Unmet Need in Surgical Site Infection Prevention Following Positive Phase 3 ResultsPETACH TIKVA,…
– Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D – Sally…
Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025; Awarded…
VANCOUVER, British Columbia and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company…
Rising Demand from Third-Party Diagnostic and Biotechnology Companies Drives CDMO Service ExpansionComprehensive CDMO services now featured on Biomerica’s updated website…
FLORHAM PARK, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused…